Join MetwareBio at ADA 84th Scientific Sessions: Elevate Your Diabetes Research

Understanding Diabetes: A Global Health Crisis

Diabetes is a chronic health condition that affects how your body turns food into energy, leading to elevated blood sugar levels. Diabetes is a major global health issue affecting over 422 million people worldwide, with the prevalence increasing steadily over recent decades. It is classified primarily into three main types: Type 1, Type 2, and gestational diabetes. Type 1 diabetes is an autoimmune condition where the body's immune system attacks and destroys insulin-producing beta cells in the pancreas, typically developing in children and young adults and requiring lifelong insulin therapy. The exact cause is unknown, but it is believed to involve a combination of genetic and environmental factors. Type 2 diabetes, the most common form accounting for about 90-95% of all diabetes cases, occurs when the body becomes resistant to insulin or when the pancreas cannot produce enough insulin. It is largely associated with obesity, physical inactivity, and poor diet, and can be managed with lifestyle changes and medication. Gestational diabetes develops during pregnancy and usually disappears after giving birth; however, it increases the mother's risk of developing Type 2 diabetes later in life and can pose risks to the baby, including higher birth weight and potential breathing problems. 

Complications of Unmanaged Diabetes

If not properly managed, diabetes can lead to severe complications, including cardiovascular disease, which increases the risk of heart attacks, strokes, and hypertension. It can also cause neuropathy, leading to nerve damage, especially in the extremities, which results in pain, tingling, or loss of sensation. Additionally, diabetes can lead to nephropathy, or kidney damage, potentially resulting in kidney failure, and retinopathy, where damage to the blood vessels in the retina causes vision problems and even blindness. Poor blood flow and nerve damage can also result in foot ulcers and infections, sometimes necessitating amputation.

The Role of the American Diabetes Association (ADA)

The American Diabetes Association (ADA) is at the forefront of the fight against diabetes, dedicated to preventing and curing the disease through research, education, and advocacy. Each year, the ADA hosts the Scientific Sessions, a premier event that gathers healthcare professionals, researchers, and industry leaders to share the latest advancements in diabetes care and management. This year marks the 84th edition of the American Diabetes Association Scientific Sessions, to be held in Orlando, FL, from June 21-24. Continuing the tradition of fostering collaboration and innovation in the field, MetwareBio is honored to be invited by the conference organizers to participate in this prestigious event. As a leading provider of metabolomics detection services, we will showcase our state-of-the-art metabolomics detection technologies and services, driving forward the advancement of diabetes care and treatment research.

MetwareBio: Pioneers in Metabolomics Detection Services

MetwareBio (Metware Biotechnology Inc.) is a metabolomics CRO focusing on developing and applying innovative metabolomics technologies to life science and health research. Based on the high-throughput, ultra-sensitive and patented widely targeted metabolomics’ technology, as well as large-curated metabolite database, MetwareBio offers ‘one-stop metabolomics and multi-omics research and analysis services’ for research institutes, hospitals and pharmaceutical companies. MetwareBio technical achievements have been presented and published in over 700 publications, including Cell, Nature Genetics, PNAS, Nature Communications, National Science Review, and many other international peer-reviewed journals. The research topics supported by MetwareBio’s metabolomics services span a wide range, including human diseases, animal nutrition, agricultural breeding, and microorganism research.

Advancing Diabetes Research with MetwareBio’s Innovations

In the realm of diabetes research, MetwareBio has played a pivotal role in supporting numerous research endeavors, facilitating the publication of groundbreaking findings. One such example is the study titled "Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes" featured in Nature Communications. This study has revealed microbial functional and metabolic dysbiosis in T1D, indicating that specific gut bacteria and metabolites may serve as novel adjuvant diagnostic, preventative, and therapeutic targets for T1D via multi-omics study and animal experiments. The study enrolled 141 subjects in the discovery cohort and 58 in the validation cohort, conducting comprehensive analyses including 16S rRNA gene sequencing, metabolomic profiling, and quantification of short-chain fatty acids utilizing their fecal samples. The results showed microbiota was characterized by decreased butyrate production and bile acid metabolism and increased lipopolysaccharide biosynthesis at the species, gene, and metabolite levels in T1D. The combination of 18 bacteria species and fecal metabolites as gut biomarkers excellently discriminated T1D from controls. The animal experiments further unraveled that gut microflora of T1D was a causative factor in the regulation of glucose metabolism. Butyrate and lipopolysaccharide exerted protective and destructive effects, respectively, on islet structure and function in the T1D mouse model. MetwareBio offered the widely-targeted metabolomics and short-chain fatty acids targeted metabolomics detection services for this research.

In addition to the aforementioned services, MetwareBio also offers untargeted metabolomics detection, as well as targeted metabolomics detection focusing on bile acids, energy metabolism, amino acids, and phytohormones, along with quantitative lipidomics detection. For more novel and interesting findings powered by MetwareBio, please see our publication webpage.

Finally, we're thrilled to announce our presence at the ADA 84th Scientific Session with a dedicated booth. Join us and explore tailored metabolomics services designed to cater to your unique requirements at MetwareBio's booth #809. We look forward to welcoming you!